Carregant...
Eculizumab and aHUS: to stop or not
In this issue of Blood, Fakhouri et al(1) provide evidence in a prospective phase 4, multicentric, noncontrolled study that discontinuing eculizumab is safe in most patients with atypical hemolytic uremic syndrome (aHUS) once they achieve complete remission. Risk of relapse was <25% overall, but...
Guardat en:
| Publicat a: | Blood |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Society of Hematology
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8109016/ https://ncbi.nlm.nih.gov/pubmed/33956069 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020010234 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|